Eli Lilly is once again taking to the road for its clinical trials, but this time it’s aiming at underrepresented trial subjects as it continues to find workarounds for the COVID-19 chaos.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,